IL279692A - A preparation containing antisense oligonucleotides and their uses for the treatment of Duchenne syndrome - Google Patents

A preparation containing antisense oligonucleotides and their uses for the treatment of Duchenne syndrome

Info

Publication number
IL279692A
IL279692A IL279692A IL27969220A IL279692A IL 279692 A IL279692 A IL 279692A IL 279692 A IL279692 A IL 279692A IL 27969220 A IL27969220 A IL 27969220A IL 279692 A IL279692 A IL 279692A
Authority
IL
Israel
Prior art keywords
treatment
composition
antisense oligonucleotide
muscular dystrophy
duchenne muscular
Prior art date
Application number
IL279692A
Other languages
English (en)
Hebrew (he)
Inventor
Satou Youhei
UNO Tomonori
NATSUKAWA Takashi
EGAWA Youichi
Original Assignee
Nippon Shinyaku Co Ltd
Satou Youhei
UNO Tomonori
NATSUKAWA Takashi
EGAWA Youichi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co Ltd, Satou Youhei, UNO Tomonori, NATSUKAWA Takashi, EGAWA Youichi filed Critical Nippon Shinyaku Co Ltd
Publication of IL279692A publication Critical patent/IL279692A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IL279692A 2018-06-26 2020-12-22 A preparation containing antisense oligonucleotides and their uses for the treatment of Duchenne syndrome IL279692A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862690270P 2018-06-26 2018-06-26
US201862739386P 2018-10-01 2018-10-01
PCT/JP2019/026393 WO2020004675A1 (ja) 2018-06-26 2019-06-26 アンチセンスオリゴヌクレオチドを含有する組成物およびデュシェンヌ型筋ジストロフィーの治療へのその使用

Publications (1)

Publication Number Publication Date
IL279692A true IL279692A (en) 2021-03-01

Family

ID=68987235

Family Applications (1)

Application Number Title Priority Date Filing Date
IL279692A IL279692A (en) 2018-06-26 2020-12-22 A preparation containing antisense oligonucleotides and their uses for the treatment of Duchenne syndrome

Country Status (21)

Country Link
US (2) US20210261963A1 (2)
EP (1) EP3815696A4 (2)
JP (3) JP7345466B2 (2)
KR (1) KR20210023988A (2)
CN (1) CN112399849A (2)
AU (2) AU2019293687B2 (2)
BR (1) BR112020026542A2 (2)
CA (1) CA3101321A1 (2)
CL (1) CL2020003367A1 (2)
CO (1) CO2020015685A2 (2)
EC (1) ECSP20083454A (2)
IL (1) IL279692A (2)
MX (2) MX2020013880A (2)
MY (1) MY209148A (2)
NZ (1) NZ770540A (2)
PE (1) PE20210630A1 (2)
PH (1) PH12020552078A1 (2)
SG (1) SG11202011554PA (2)
TW (1) TW202035692A (2)
WO (1) WO2020004675A1 (2)
ZA (1) ZA202007682B (2)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020227825B2 (en) 2019-02-27 2026-03-26 Stoke Therapeutics, Inc. Antisense oligomers for treatment of conditions and diseases
CN115867657A (zh) 2020-05-11 2023-03-28 斯托克制药公司 用于治疗疾患和疾病的opa1反义寡聚物
IL307937A (en) 2021-04-30 2023-12-01 Sarepta Therapeutics Inc Treatment methods for muscular dystrophy
CN119013401A (zh) 2022-03-17 2024-11-22 萨勒普塔医疗公司 二氨基磷酸酯吗啉代寡聚物缀合物
KR20250006069A (ko) * 2022-05-05 2025-01-10 바이오마린 파머수티컬 인크. 뒤시엔느 근이영양증을 치료하는 방법
CN121194802A (zh) * 2023-02-14 2025-12-23 斯托克制药公司 反义寡聚物调配物
WO2024233303A1 (en) * 2023-05-05 2024-11-14 Biomarin Pharmaceutical Inc. Dystrophin exon skipping oligonucleotides

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU655164B2 (en) 1989-12-20 1994-12-08 Antivirals Inc. Uncharged morpholino-based polymers having phosphorous-containing chiral intersubunit linkages
EP2392660A3 (en) 2002-11-25 2012-03-28 Masafumi Matsuo ENA Nucleic Acid Drugs Modifying Splicing in mRNA Precursor
EP2933332A1 (en) 2004-06-28 2015-10-21 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
WO2006038608A1 (ja) 2004-10-05 2006-04-13 Nippon Shinyaku Co., Ltd. オリゴ二本鎖ｒｎａ及び医薬組成物
EP1886688A4 (en) 2005-05-30 2013-01-09 Nippon Shinyaku Co Ltd METHOD FOR PRODUCING PREPARATION OF A NUCLEIC ACID-CONTAINING COMPLEX
RU2606627C2 (ru) 2007-11-15 2017-01-10 Серепта Терапьютикс,Инк. Способ синтеза морфолиновых олигомеров
US8084601B2 (en) 2008-09-11 2011-12-27 Royal Holloway And Bedford New College Royal Holloway, University Of London Oligomers
BR122020021379B1 (pt) 2008-10-24 2021-05-11 Sarepta Therapeutics, Inc. oligômero morfolino fosforodiamidato, composição que compreende o mesmo e uso do dito oligômero para tratar distrofia muscular
TWI541024B (zh) * 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
NZ627896A (en) * 2012-01-27 2016-11-25 Biomarin Technologies B V Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
US20140315977A1 (en) * 2013-03-14 2014-10-23 Sarepta Therapeutics, Inc. Exon skipping compositions for treating muscular dystrophy
US20140329762A1 (en) 2013-03-15 2014-11-06 Sarepta Therapeutics, Inc. Compositions for treating muscular dystrophy
DK3015467T3 (da) * 2013-05-24 2025-02-10 Ajinomoto Kk Morpholino-oligonukleotidfremstillingsfremgangsmåde
WO2017059131A1 (en) * 2015-09-30 2017-04-06 Sarepta Therapeutics, Inc. Methods for treating muscular dystrophy
FR3044926B1 (fr) * 2015-12-09 2020-01-31 Genethon Outils de therapie genique efficaces pour le saut de l'exon 53 de la dystrophine

Also Published As

Publication number Publication date
CL2020003367A1 (es) 2021-05-24
BR112020026542A2 (pt) 2021-04-06
MX2025001486A (es) 2025-03-07
JP7595719B2 (ja) 2024-12-06
PH12020552078A1 (en) 2021-05-31
TW202035692A (zh) 2020-10-01
WO2020004675A1 (ja) 2020-01-02
CN112399849A (zh) 2021-02-23
SG11202011554PA (en) 2020-12-30
ECSP20083454A (es) 2021-01-29
AU2019293687B2 (en) 2025-10-02
EP3815696A1 (en) 2021-05-05
CO2020015685A2 (es) 2021-04-30
ZA202007682B (en) 2024-04-24
AU2019293687A1 (en) 2021-01-07
CA3101321A1 (en) 2020-01-02
US20240158792A1 (en) 2024-05-16
JP2025028961A (ja) 2025-03-05
MX2020013880A (es) 2021-03-09
JP7345466B2 (ja) 2023-09-15
MY209148A (en) 2025-06-24
EP3815696A4 (en) 2022-11-30
NZ770540A (en) 2025-12-19
JP2023171731A (ja) 2023-12-05
KR20210023988A (ko) 2021-03-04
PE20210630A1 (es) 2021-03-23
AU2025283628A1 (en) 2026-01-22
JPWO2020004675A1 (ja) 2021-07-15
US20210261963A1 (en) 2021-08-26

Similar Documents

Publication Publication Date Title
IL279692A (en) A preparation containing antisense oligonucleotides and their uses for the treatment of Duchenne syndrome
IL274023A (en) Antisense oligomers for the treatment of condition- and disease-based nonsense-mediated RNA decay
IL277889A (en) Preparations of oligonucleotides and methods of using them
SG11202010131QA (en) Oligonucleotide compositions and methods of use thereof
HUE047502T2 (hu) Antiszensz nukleinsav Duchenne izomsorvadás kezelésében történõ alkalmazásra
IL288259A (en) Modified Gapmer Oligonucleotides and Methods of Use
IL273173A (en) RNAi agents and preparations for suppressing the expression of angiopoietin-like 3 (ANGPTL3) and methods of use
ES3063421T3 (en) Modified oligonucleotides for use in treatment of tauopathies
GB201714027D0 (en) Antisense oligonucleotides for the treatment of huntington's disease
IL304674A (en) Reagents for the treatment of oculopharyngeal muscular dystrophy (opmd) and their uses
IL257296B (en) Methods of sedation and intravenous vehicle for use during critical care
IL286872A (en) Antisense oligonucleotides for the treatment of usher syndrome
IL272036A (en) Methods and compositions for treating pain using capsaicin
ZA201908276B (en) Charge-tagged nucleotides and methods of use thereof
ZA201807589B (en) Reagents for treatment of oculopharyngeal muscular dystrophy (opmd) and use thereof
HK40086853B (en) Antisense oligomers for treatment of non-sense mediated rna decay based conditions and diseases
HK40086853A (en) Antisense oligomers for treatment of non-sense mediated rna decay based conditions and diseases
IL262013A (en) Composition for the treatment of duchenne muscular dystrophy
GB201612920D0 (en) Composition for the treatment of Duchenne Muscular Dystrophy
GB201605383D0 (en) Composition for the treatment of duchenne muscular dystrophy
GB201605380D0 (en) Composition for the treatment of duchenne muscular dystrophy